Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since results from one of the first clinical trials of such a therapeutic approach in patients with NSCLC were reported in 2018 (ref. 19), the efficacy and safety of neoadjuvant ICIs have been firmly established in multiple tumour types, with FDA approvals for two indications (NSCLC20,120 and triple-negative breast cancer8).”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [19]
Citations
Cites
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Gainor, J. F., Shaw, A. T., Sequist, L. V., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,250
(2017) · doi:10.1158/1078-0432.ccr-16-3133 · Cited by 831
Signaling Through OX40 Enhances Antitumor Immunity
Jensen, S. M., Maston, L. D., Gough, M. J., Ruby, C. E., Redmond, W. L., Crittenden, M., Li, Y., Puri, S., Poehlein, C. H., Morris, N., et al. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.013 · Cited by 146
Imbalance of dendritic cell co-stimulation in COPD
Stoll, P., Ulrich, M., Bratke, K., Garbe, K., Virchow, J. C., Jr., & Lommatzsch, M. (2015) · Respiratory Research · doi:10.1186/s12931-015-0174-x · Cited by 36
Cited by
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
Chalabi, M., Fanchi, L. F., Dijkstra, K. K., Van den Berg, J. G., Aalbers, A. G., Sikorska, K., Lopez-Yurda, M., Grootscholten, C., Beets, G. L., Snaebjornsson, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0805-8 · Cited by 1,417
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Sosman, J. A., Atkins, M. B., Leming, P. D., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2187 · Cited by 619
The emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Xu, X., Sun, Q., Liang, X., Chen, Z., Zhang, X., Zhou, X., Li, M., Tu, H., Liu, Y., Tu, S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02664 · Cited by 347
Rothschild, S. I., Zippelius, A., Eboulet, E. I., Savic Prince, S., Betticher, D., Bettini, A., Früh, M., Joerger, M., Lardinois, D., Gelpke, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00276 · Cited by 333
Genova, C., Dellepiane, C., Carrega, P., Sommariva, S., Ferlazzo, G., Pronzato, P., Gangemi, R., Filaci, G., Coco, S., & Croce, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.799455 · Cited by 260
Wise-Draper, T. M., Gulati, S., Palackdharry, S., Hinrichs, B. H., Worden, F. P., Old, M. O., Dunlap, N. E., Kaczmar, J. M., Patil, Y., Riaz, M. K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3351 · Cited by 197
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
Suresh, K., Naidoo, J., Zhong, Q., Xiong, Y., Mammen, J., de Flores, M. V., Cappelli, L., Balaji, A., Palmer, T., Forde, P. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128654 · Cited by 192
Padinharayil, H., Varghese, J., John, M. C., Rajanikant, G. K., Wilson, C. M., Al-Yozbaki, M., Renu, K., Dewanjee, S., Sanyal, R., Dey, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.023 · Cited by 159
PD-1/PD-L1 Inhibitors in Cervical Cancer
Liu, Y., Wu, L., Tong, R., Yang, F., Yin, L., Li, M., You, L., Xue, J., & Lü, Y. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00065 · Cited by 164
Duhen, R., Ballesteros‐Merino, C., Frye, A. K., Tran, E., Rajamanickam, V., Chang, S., Koguchi, Y., Bifulco, C. B., Bernard, B. M., Leidner, R. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21383-1 · Cited by 156
Li, B., Zhang, B., Wang, X., Zeng, Z., Huang, Z., Zhang, L., Wei, F., Ren, X., & Yang, L. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1807291 · Cited by 120
“Surprisingly, neoadjuvant immunotherapy appears to rewrite the current status of treatment for early cancer.(8) Blocking programmed cell death-1 (PD-1)/ PD-1 ligand 1 (PD-L1) is widely regarded as a successful strategy in normalization cancer immunotherapy.”
BackgroundImmunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges
Kunimasa, K., & Goto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020597 · Cited by 110
Deng, H., Zhao, Y., Cai, X., Chen, H., Cheng, B., Zhong, R., Li, F., Xiong, S., Li, J., Liu, J., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103582 · Cited by 109
Sato, Y., Fu, Y., Liu, H., Lee, M. Y., & Shaw, M. H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08974-3 · Cited by 109
Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer
Cascone, T., Fradette, J. J., Pradhan, M., & Gibbons, D. L. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037895 · Cited by 100
Tao, X., Li, N., Wu, N., He, J., Ying, J., Gao, S., Wang, S., Wang, J., Wang, Z., Ling, Y., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04711-3 · Cited by 95
Chuntova, P., Chow, F. E., Watchmaker, P. B., Galvez, M., Heimberger, A. B., Newell, E. W., Diaz, A. A., DePinho, R. A., Li, M. O., Wherry, E. J., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa277 · Cited by 96
Cellular determinants and therapeutic implications of inflammation in pancreatic cancer
Stone, M. L., & Beatty, G. L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.012 · Cited by 90
Lévesque, S., Le Naour, J., Pietrocola, F., Paillet, J., Kremer, M., Castoldi, F., Baracco, E. E., Wang, Y., Vacchelli, E., Stoll, G., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1657375 · Cited by 86
Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation
Borden, E. S., Buetow, K. H., Wilson, M. A., & Hastings, K. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.836821 · Cited by 78
“Tumor-specific neoantigens are also the target of cancer immunotherapy with immune checkpoint inhibitors (16, 17).”
BackgroundMyeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
Peranzoni, E., Ingangi, V., Masetto, E., Pinton, L., & Marigo, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01590 · Cited by 86
“In another cohort, neoadjuvant Nivolumab in resectable NSCLC induced necrotic areas with large infiltrates of lymphocytes and foamy macrophages in tumors of patients with major pathological response at surgery (96, 97).”
BackgroundRepresentative Sequencing: Unbiased Sampling of Solid Tumor Tissue
Litchfield, K., Stanislaw, S., Spain, L., Gallegos, L. L., Rowan, A., Schnidrig, D., Rosenbaum, H., Harlé, A., Au, L., Hill, S. M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107550 · Cited by 86
Kim, J. W., Márquez, C. P., Kostyrko, K., Koehne, A. L., Marini, K. D., Simpson, D. R., Lee, A. G., Leung, S. G., Sayles, L. C., Shrager, J. B., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0612-2 · Cited by 84
Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer
Boumber, Y. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.120 · Cited by 79
Yang, S., Cao, B., Zhou, G., Zhu, L., Wang, L., Zhang, L., Kwok, H. F., Zhang, Z., & Zhao, Q. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01089 · Cited by 76
El-Osta, H. E., & Jafri, S. H. R. (2019) · Immunotherapy · doi:10.2217/imt-2018-0086 · Cited by 78
Cell and tissue engineering in lymph nodes for cancer immunotherapy
Najibi, A. J., & Mooney, D. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.023 · Cited by 80
Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies
Ji, Z., Shen, J., Lan, Y., Yi, Q., & Liu, H. (2023) · MedComm · doi:10.1002/mco2.308 · Cited by 82
Progress in advanced nanotherapeutics for enhanced photodynamic immunotherapy of tumor
Xiao, W., Song, M., Jiang, G., Liang, M., Chen, C., Yang, Z., & Zou, L. (2022) · Theranostics · doi:10.7150/thno.73566 · Cited by 68
Li, M. S. C., Mok, K. K. S., & Mok, T. S. K. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4444 · Cited by 76
Jin, W., Yang, Q., Chi, H., Wei, K., Zhang, P., Zhao, G., Chen, S., Xia, Z., & Li, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1025330 · Cited by 77
“Many immunotherapies have received durable clinical responses, including pancreatic (3), gastric (4), bladder (5), and lung cancer (6); however, limited response rates and unclear underlying mechanisms hinder further immunotherapy development, so only subsets of cancer patients can bene fi t from…”
BackgroundTolba, M. F. (2020) · International Journal of Cancer · doi:10.1002/ijc.33056 · Cited by 73
Godoy, L. A., Chen, J., Ma, W., Lally, J., Toomey, K. A., Rajappa, P., Sheridan, R., Mahajan, S., Stollenwerk, N. S., Phan, C. T., et al. (2023) · Biomarker Research · doi:10.1186/s40364-022-00444-7 · Cited by 74
Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy
Goleva, E., Lyubchenko, T. A., Kraehenbuehl, L., Lacouture, M. E., Leung, D. Y. M., & Kern, J. A. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.03.003 · Cited by 64
Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-Small Cell Lung Cancer
Zhang, P., Dai, J., Sun, F., Xia, H., He, W., Duan, L., Liu, M., Zhao, D., Zhu, Y., & Jiang, G. (2022) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2022.01.039 · Cited by 62
Shen, D., Wang, J., Wu, J., Chen, S., Li, J., Liu, J., Chen, Q., & Jiang, Y. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-21-103 · Cited by 62
Liu, S., Knochelmann, H. M., Lomeli, S. H., Hong, A., Richardson, M. S., Yang, Z., Lim, R. J., Wang, Y., Dumitras, C., Krysan, K., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100411 · Cited by 66
“For example, in individuals with early-stage NSCLC, only two experienced a radiographic partial response despite a high rate of major pathologic response, and two tumors that had increased in size after treatment harbored minimal residual tumor in the surgical specimen.(48) All tumors in this study that responded path…”
BackgroundEmerging immunotherapies for malignant glioma: from immunogenomics to cell therapy
Dunn, G. P., Cloughesy, T. F., Maus, M. V., Prins, R. M., Reardon, D. A., & Sonabend, A. M. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa154 · Cited by 61
Duan, H., Wang, T., Luo, Z., Tong, L., Dong, X., Zhang, Y., Afzal, M. Z., Correale, P., Liu, H., Jiang, T., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-130 · Cited by 58
Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives
Lazzari, C., Spagnolo, C. C., Ciappina, G., Pietro, M. D., Squeri, A., Passalacqua, M. I., Marchesi, S., Gregorc, V., & Santarpía, M. (2023) · Current Oncology · doi:10.3390/curroncol30040280 · Cited by 62
“Results showed a significant benefit in patients with stage II-IIIA and PD-L1 ≥ 1%, as assessed by the Ventana (SP263) assay, and in all patients with stage II-IIIA NSCLC, irrespective of PD-L1 expression.”
BackgroundInfluentialRytlewski, J. A., Deng, S., Xie, T., Davis, C. B., Robins, H. S., Yusko, E. C., & Bienkowska, J. R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213684 · Cited by 53
A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies
Qu, J., Wang, L., Jiang, M., Zhao, D., Wang, Y., Zhang, F., Li, J., & Zhang, X. (2020) · Cancer Management and Research · doi:10.2147/cmar.s257188 · Cited by 52
Current status and future perspectives of immunotherapy in bladder cancer treatment
Wu, Z., Liu, J., Dai, R., & Wu, S. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1768-y · Cited by 53
Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
Lee, J. M., Tsuboi, M., & Brunelli, A. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2021.06.069 · Cited by 49
Pradhan, M., Chocry, M., Gibbons, D. L., Sepesi, B., & Cascone, T. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-573 · Cited by 48
Molecular imaging to support cancer immunotherapy
van de Donk, P. P., Oosting, S. F., Knapen, D. G., van der Wekken, A. J., Brouwers, A. H., Hooge, M. N. L., de Groot, D. J., & de Vries, E. G. E. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004949 · Cited by 44
Effect and biomarker of Nivolumab for non–small-cell lung cancer
Wang, L., Zhao, D., Qin, K., Rehman, F. U., & Zhang, X. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109199 · Cited by 46
Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC
Lee, J. M., Kim, A. W., Marjański, T., Falcoz, P., Tsuboi, M., Wu, Y.-L., Sun, S. W., & Gitlitz, B. J. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100221 · Cited by 49
Relecom, A., Merhi, M., Inchakalody, V. P., Shahab Uddin, M. S., Rinchai, D., Bedognetti, D., & Dermime, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01872-3 · Cited by 44
Novel treatment strategies for early-stage lung cancer: the oncologist’s perspective
Indini, A., Rijavec, E., Bareggi, C., & Grossi, F. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.02.46 · Cited by 44
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic
Etxeberría, I., Bolaños, E., Teijeira, Á., Garasa, S., Yanguas, A., Azpilikueta, A., Kavanaugh, W. M., Vasiljeva, O. S., Belvin, M. P., Howng, B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025930118 · Cited by 42
Wang, Y., Chen, D., Liu, Y., Shi, D., Duan, C., Li, J., Shi, X., Zhang, Y., Yu, Z., Sun, N., et al. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-05992-w · Cited by 39
Liu, Y., Altreuter, J., Bodapati, S., Cristea, S., Wong, C. J., Wu, C. J., & Michor, F. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100444 · Cited by 48
“28,62,84,86,87 However, in the post-treatment biopsies of responders, there was 10-fold more TCR clonal expansion than in non-responders, while the tumor specificity of these clones was not assessed.”
BackgroundMiyawaki, T., Kenmotsu, H., Mori, K. P., Miyawaki, E., Mamesaya, N., Kawamura, T., Kobayashi, H., Omori, S., Wakuda, K., Ono, A., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.02.012 · Cited by 39
Kang, L., Huang, J., Luo, H., Luo, C. H., Zhu, X., Bu, F., Xiao, H., Li, X., & Zhu, Z. (2020) · Aging · doi:10.18632/aging.102979 · Cited by 41
Tumor-Infiltrating Lymphocytes—Location for Prognostic Evaluation
Peled, M., Onn, A., & Herbst, R. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3803 · Cited by 38
Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology
Mylvaganam, G., Yanez, A. G., Maus, M. V., & Walker, B. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02109 · Cited by 38
“Remarkable examples of immune-mediated disease-free remissions have been achieved for some previously intractable malignancies, such as melanoma (5–7), non-small cell lung cancer (8, 9), and chemotherapy-refractory leukemia and lymphoma (10, 11).”
BackgroundLung cancer mortality in Europe and the USA between 2000 and 2017: an observational analysis
Jani, C., Marshall, D. C., Singh, H., Goodall, R. J., Shalhoub, J., Omari, O. A., Salciccioli, J. D., & Thomson, C. C. (2021) · ERJ Open Research · doi:10.1183/23120541.00311-2021 · Cited by 37
Wang, S., Liu, L., Tian, L., Xu, P., Li, S., Hu, L., Xia, Y., Ding, Y., Wang, J., & Li, S. (2024) · Advanced Materials · doi:10.1002/adma.202403296 · Cited by 39
Advances in theranostic biomarkers for tumor immunotherapy
Bellesœur, A., Torossian, N., Amigorena, S., & Romano, E. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.02.005 · Cited by 35
Learning from the nexus of autoimmunity and cancer
Mangani, D., Yang, D., & Anderson, A. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.022 · Cited by 33
Weissferdt, A., Pataer, A., Swisher, S. G., Heymach, J. V., Gibbons, D. L., Cascone, T., & Sepesi, B. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.014 · Cited by 34
You, W., Shang, B., Sun, J., Liu, X., Su, L., & Jiang, S. (2020) · Oncology Reports · doi:10.3892/or.2020.7643 · Cited by 36
Ahern, E. S., Cubitt, A., Ballard, E. L., Teng, M. W. L., Dougall, W. C., Smyth, M. J., Godbolt, D., Naidoo, R., Goldrick, A., & Hughes, B. G. M. (2019) · Trials · doi:10.1186/s13063-019-3951-x · Cited by 33
Iivanainen, S., & Koivunen, J. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020556 · Cited by 30
Xia, W.-Y., Feng, W., Zhang, C., Shen, Y., Zhang, Q., Yu, W. J., Cai, X., & Fu, X. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-827 · Cited by 32
Gross, E. E., Li, M., Yin, M., Orcutt, D. J., Hussey, D., Trott, E., Holt, S. K., Dwyer, E. R., Kramer, J. H., Oliva, K., et al. (2022) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2022.08.013 · Cited by 33
Preclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy
Chen, M., & Wang, S.-L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111717 · Cited by 30
Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
Chen, Y., Yan, B., Xu, F., Hui, Z., Zhao, G., Liu, J., Zhang, H., Zeng, Z., Zhang, R., Provencio, M., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-329 · Cited by 30
Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy
Weissferdt, A., Leung, C. H., Lin, H. Y., Sepesi, B., William, W. N., Swisher, S. G., Cascone, T., Lee, J. J., & Pataer, A. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100353 · Cited by 30
Current status and prospect of immunotherapy for colorectal cancer
Yang, W., Zheng, H., Lv, W., & Zhu, Y. (2023) · International Journal of Colorectal Disease · doi:10.1007/s00384-023-04553-z · Cited by 29
Effect of Extracellular Vesicles Derived From Tumor Cells on Immune Evasion
Liu, X., To, K. K. W., Zeng, Q., & Fu, L. (2025) · Advanced Science · doi:10.1002/advs.202417357 · Cited by 32
Semyachkina-Glushkovskaya, O. V., Terskov, A. V., Khorovodov, A. P., Telnova, V., Blokhina, I., Saranceva, E. I., & Kurths, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122612 · Cited by 28
Yang, G., Su, X., Huang, Y., Luo, G., Wang, Z., Cai, P., Zheng, Y., Bei, T., Huang, M., Bai, Y., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04273-6 · Cited by 31
Lian, W., Jiang, D., Lin, W., Jiang, M., Zhang, Y., Wang, H. Z., & Zhao, L. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.87440 · Cited by 27
Bandini, S., Ulivi, P., & Rossi, T. (2024) · Cells · doi:10.3390/cells13040337 · Cited by 29
Cui, P., Li, J., Tao, H., Li, X., Wu, L., Ma, J., Wang, H., Liu, T., Zhang, M., & Hu, Y. (2023) · Oncogene · doi:10.1038/s41388-023-02805-4 · Cited by 28
Cho, Y. A., Kim, D., Lee, B., Shim, J., & Suh, Y. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-021-03710-0 · Cited by 27
Gao, J., Zhang, L.-X., Ao, Y.-Q., Jin, C., Zhang, P., Wang, H., Wang, S., Lin, M., Jiang, J.-H., & Ding, J. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215774 · Cited by 26
Liu, J., Xu, X., Zhong, H., Yu, M., Abuduaini, N., Zhang, S., Yang, X. Y., & Feng, B. (2024) · Biomedicines · doi:10.3390/biomedicines12071446 · Cited by 24
Self-citationRaimondi, A., Randon, G., Sepe, P., Claps, M., Verzoni, E., de Braud, F., & Procopio, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174263 · Cited by 25
Immune Modulation in Lung Cancer: Current Concepts and Future Strategies
Gaissmaier, L., & Christopoulos, P. (2020) · Respiration · doi:10.1159/000510385 · Cited by 30
Zhang, F., Qiu, B., Ji, Y., Guo, W., Li, N., Xue, Q., Gao, S., & He, J. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1007 · Cited by 27
Immunotherapy for resectable lung cancer
Dennehy, C., Conroy, M. R., & Forde, P. M. (2025) · Cancer · doi:10.1002/cncr.35849 · Cited by 28
Brabo, E. P., Moraes, A. B., & Neto, L. V. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01306-5 · Cited by 25
Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
Huynh, C., Walsh, L. A., & Spicer, J. D. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-509 · Cited by 25
Huang, L., Li, L., Zhou, Y., Yang, Z., Wang, M., Gao, Y., Yang, Y., Yang, F., Liu, B., Hong, X., et al. (2020) · Journal of Cancer · doi:10.7150/jca.49213 · Cited by 26
Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients
Fei, Y., Yu, J., Li, Y., Li, L., Zhou, S., Zhang, T., Li, L., Qiu, L., Meng, B., Pan, Y., et al. (2020) · Journal of Cancer · doi:10.7150/jca.47816 · Cited by 23
Guo, H., Diao, L., Zhou, X., Chen, J.-N., Zhou, Y., Fang, Q., He, Y., Dziadziuszko, R., Zhou, C., & Hirsch, F. R. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-96 · Cited by 24
Greenwald, N. F., Nederlof, I., Sowers, C., Ding, D. Y., Park, S., Kong, A., Houlahan, K. E., Varra, S. R., de Graaf, M., Geurts, V. C. M., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01114-5 · Cited by 29
Panian, J. A., Saidian, A., Hakimi, K. N., Ajmera, A., Anderson, W. J., Barata, P. C., Berg, S. A., Signoretti, S., Chang, S. L., D’Andrea, V. D., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad166 · Cited by 22
Luo, H., Wang, W., Mai, J., Yin, R., Cai, X., & Li, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1267918 · Cited by 22
Self-citationSharma, S., Singh, N., Turk, A. A., Wan, I., Guttikonda, A., Dong, J. L., Zhang, X., & Opyrchal, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i13.1815 · Cited by 27
Wiegand, S., Wichmann, G., & Dietz, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00191 · Cited by 22
Sun, G., Liu, H., Shi, X., Tan, P., Tang, W., Chen, X., Sun, G., Yang, W., Kong, X., Zheng, Z., et al. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5364 · Cited by 22
Han, R. F., Zhang, Y., Wang, T., Xiao, H., Luo, Z., Shen, C., Li, J., Zhao, C., Li, L., Zhu, M., et al. (2022) · Cancer Science · doi:10.1111/cas.15778 · Cited by 23
Metadata
- Authors
- Yang, X., Yin, R., & Xu, L.
- Affiliations
- The First People's Hospital of Changzhou (CN)
- Jiangsu Cancer Hospital (CN)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-08-30
- Volume
- 379
- Issue
- 9
- Pages
- e14-e14
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2982617740
- Cited by
- 277
- References
- 8
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 25 · 2023: 65 · 2022: 40 · 2021: 49 · 2020: 49 · 2019: 28 · 2018: 7
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- neoadjuvant immunotherapy, anti-PD-1 therapy, lung cancer, resectable non-small cell lung cancer, immune checkpoint inhibitors, surgical resection
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Pancreatic Neoplasms, Neoadjuvant Therapy, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.